Abstract 11785: National Hospitalizations for Supraventricular Tachycardia in the United States, 2010 Through 2017

Abstract

Background: Little data exists describing the national burden of supraventricular tachycardia (SVT) related hospitalizations on US healthcare system. The objectives of this study are to examine the temporal trends of SVT-related hospitalizations in the United States and to compare patient characteristics, outcomes, and comorbid diagnoses. Methods: Using the Nationwide Readmission Database from 2010 through 2017, we identified adult (age >17 years) SVT-related hospitalizations using International Classification of Diseases, 9 th /10th Revision, Clinical Modification codes- 427.0/I47.1 as the principal discharge diagnosis. Results: There were 192,853 adult hospitalizations for SVT from 2010 to 2017 across United States. The number of hospitalizations increased from 22,313 in 2010 to 39,216 in 2017. Mean age was 63.9 years, 56.8% females and 55.8% Medicare insured. The proportion of comorbid diagnoses in overall cohort: hypertension 66.4%, diabetes 26.9%, hyperlipidemia 42.8%, coronary artery disease 31.6%, atrial fibrillation 30.0%, cerebrovascular disease 3.4%, renal disease 18.8%, liver disease 4.2% and chronic pulmonary disease 14.7%. From 2010 to 2017, following trends were observed: mean age (63.7 years to 64.1 years), females (59.5% to 54.4%), Medicare insured (53.8% to 57.0%), hypertension (62.2% to 70.0%), diabetes (25.3% to 27.5%), hyperlipidemia (39.6% to 45.0%), coronary artery disease (28.6% to 34.8%), cerebrovascular disease (3.0% to 3.3%), renal disease (12.9% to 23.0%), liver disease (4.5% to 2.8%) and chronic pulmonary disease (13.0% to 16.4%). The overall unadjusted in-hospital mortality was 0.6% and mean length of stay was 3.0 days. The trends of mortality and length of stay changed as follows: 0.5% in 2010 to 0.6% in 2017 and 2.9 days to 3.1 days respectively. Mean hospital charges (in USD) were 40,943 and increased from 31,755 in 2010 to 47,830 in 2017. Conclusions: The number of hospitalizations for SVT have increased among US adults from 2010 to 2017. The proportion of comorbid chronic diseases, in-hospital mortality and the hospitalization charges also increased during the period of analysis.